Pristimerin synergizes with gemcitabine through abrogating Chk1/53BP1-mediated DNA repair in pancreatic cancer cells

Prevention of DNA Replication Stress by CHK1 Leads to Chemoresistance Despite a DNA Repair Defect in Homologous Recombination in Breast Cancer

(2020) Felix Meyer et al.   Cells

Exploiting DNA Replication Stress for Cancer Treatment

(2019) Tajinder Ubhi et al.   CANCER RESEARCH

Anti-Cancer Effects of Pristimerin and the Mechanisms: A Critical Review

(2019) Jia-jun Li et al.   Frontiers in Pharmacology

ATR/CHK1 inhibitors and cancer therapy

(2018) Zhaojun Qiu et al.   RADIOTHERAPY AND ONCOLOGY

Inhibition of checkpoint kinase 1 following gemcitabine-mediated S phase arrest results in CDC7- and CDK2-dependent replication catastrophe

(2018) Nicholas Warren et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Pancreatic cancer incidence trends: evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data

(2017) Vanessa L Gordon-Dseagu et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

The essential kinase ATR: ensuring faithful duplication of a challenging genome

(2017) Joshua C. Saldivar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Pancreatic Cancer Chemoresistance to Gemcitabine

(2017) Manoj Amrutkar et al.   Cancers

Combenefit: an interactive platform for the analysis and visualization of drug combinations

(2016) Giovanni Y. Di Veroli et al.   BIOINFORMATICS

Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry

(2016) Leslie A. Parsels et al.   CELL CYCLE

CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus

(2015) S.-B. Koh et al.   CANCER RESEARCH

Exploiting replicative stress to treat cancer

(2015) Matthias Dobbelstein et al.   NATURE REVIEWS DRUG DISCOVERY

Regulated degradation of Chk1 by chaperone-mediated autophagy in response to DNA damage

(2015) Caroline Park et al.   Nature Communications

Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer

(2014) Lucas de Sousa Cavalcante et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway

(2014) Marco Lo Iacono et al.   INTERNATIONAL JOURNAL OF CANCER

Pristimerin, a quinonemethide triterpenoid, induces apoptosis in pancreatic cancer cells through the inhibition of pro-survival Akt/NF-κB/mTOR signaling proteins and anti-apoptotic Bcl-2

(2014) DORRAH DEEB et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

BRCA2 and RAD51 Promote Double-Strand Break Formation and Cell Death in Response to Gemcitabine

(2014) R. M. Jones et al.   MOLECULAR CANCER THERAPEUTICS

The causes of replication stress and their consequences on genome stability and cell fate

(2014) Indiana Magdalou et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo

(2013) Ryan Montano et al.   BMC CANCER

The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design

(2013) Ruth Thompson et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer

(2013) N. Awasthi et al.   CARCINOGENESIS

Causes and consequences of replication stress

(2013) Michelle K. Zeman et al.   NATURE CELL BIOLOGY

53BP1: pro choice in DNA repair

(2013) Michal Zimmermann et al.   TRENDS IN CELL BIOLOGY

53BP1 regulates DNA resection and the choice between classical and alternative end joining during class switch recombination

(2010) Anne Bothmer et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Chk1 promotes replication fork progression by controlling replication initiation

(2010) E. Petermann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Reconstitution of RPA-covered single-stranded DNA-activated ATR-Chk1 signaling

(2010) J.-H. Choi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics

(2010) Cynthia X. Ma et al.   TRENDS IN MOLECULAR MEDICINE

Targeting Inflammatory Pathways by Triterpenoids for Prevention and Treatment of Cancer

(2010) Vivek R. Yadav et al.   Toxins

Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells

(2009) L. A. Parsels et al.   MOLECULAR CANCER THERAPEUTICS

Detection of S-phase cell cycle progression using 5-ethynyl-2′-deoxyuridine incorporation with click chemistry, an alternative to using 5-bromo-2′-deoxyuridine antibodies

(2008) Suzanne B. Buck et al.   BIOTECHNIQUES